abstract |
The invention relates to the treatment of autoimmune and demyelinating diseases and, in particular, the treatment of multiple sclerosis. The treatment consists of the administration of P2X purinergic receptor antagonists, which leads to a remission of the symptoms associated with said type of diseases. The aforementioned result has been demonstrated using both in vitro cell models and animal models. |